person · Reporting owner
Godshall Douglas Evan
Disclosed activity across 3 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| IMMUNIC, INC.VTL · Entity 6306 | Director | September 19, 2018 | September 21, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
IMMUNIC, INC.
Report date September 19, 2018 · Filed September 21, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2018-09-19 transaction · row 1
1 source rowRow 1 · 2018-09-19 · Sale · Disposed 69,375 · Balance 0 F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.34 to $0.35. The reporting person undertakes to provide Vital Therapies, Inc., any security holder of Vital Therapies, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price range set forth in this footnote (1) to this Form 4. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.34 to $0.35. The reporting person undertakes to provide Vital Therapies, Inc., any security holder of Vital Therapies, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price range set forth in this footnote (1) to this Form 4.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
EyePoint, Inc.
Report date June 22, 2021 · Filed June 23, 2021
Section 16 reporting ended · disclosed 2021-06-23. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 8,016 |
Reported balance
After 2021-06-22 transaction · row 1
1 source rowRow 1 · 2021-06-22 · Exercise / conversion · Acquired 2,500 · Balance 8,016 |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2021-06-22 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-06-22 · Exercise / conversion · Acquired 2,500 · Balance 0 F1: The grants were approved by the Compensation Committee on February 9, 2021, subject to stockholder approval of an amendment to increase the number of shares in the Company's 2016 Plan. The shareholders approved the amendment on June 22, 2021. F2: The Restricted Stock grant vested immediately upon Mr. Godshall's departure from the Board on June 22, 2021. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.13 · Expires 2023-06-22 | Direct | 11,000 |
Reported balance
After 2021-06-22 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2021-06-22 · Grant · Acquired 11,000 · Balance 11,000 F1: The grants were approved by the Compensation Committee on February 9, 2021, subject to stockholder approval of an amendment to increase the number of shares in the Company's 2016 Plan. The shareholders approved the amendment on June 22, 2021. F3: The option to purchase vested immediately upon Mr. Godshall's departure from the Board on June 22, 2021. |
Filing footnotes · ownership attribution and instrument terms
F1: The grants were approved by the Compensation Committee on February 9, 2021, subject to stockholder approval of an amendment to increase the number of shares in the Company's 2016 Plan. The shareholders approved the amendment on June 22, 2021.
F2: The Restricted Stock grant vested immediately upon Mr. Godshall's departure from the Board on June 22, 2021.
F3: The option to purchase vested immediately upon Mr. Godshall's departure from the Board on June 22, 2021.
Shockwave Medical, Inc.
Report date May 31, 2024 · Filed May 31, 2024
Section 16 reporting ended · disclosed 2024-05-31. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2024-05-31 transaction · row 1
1 source rowRow 1 · 2024-05-31 · Disposition to issuer · Disposed 151,629 · Balance 0 F1: This Form 4 reports the disposition of securities pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of April 4, 2024, by and among the Issuer, Johnson & Johnson ("J&J"), and Sweep Merger Sub, Inc., a wholly owned subsidiary of J&J ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer (the "Merger"), effective as of the effective time of the Merger (the "Effective Time"), with the Issuer surviving the Merger as a wholly owned subsidiary of J&J. As a result of the Merger, at the Effective Time, each outstanding share of common stock, par value $0.001 per share, of the Issuer ("Common Stock") outstanding immediately prior to the Effective Time (excluding Excluded Shares and any Dissenting Company Shares, each as defined in the Merger Agreement) was automatically converted into the right to receive $335.00 in cash (the "Merger Consideration"), F2: (Continued from Footnote 1) without interest and less any applicable withholding taxes. Additionally, pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit ("RSU") outstanding immediately prior to the Effective Time, whether vested or unvested, was cancelled and converted into the right to receive a cash amount, without interest and less any applicable withholding taxes, equal to the product of (i) the aggregate number of shares of Common Stock underlying such RSU immediately prior to the Effective Time and (ii) the Merger Consideration. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $3.42 · Expires 2027-05-09 | Direct | 0 |
Reported balance
After 2024-05-31 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2024-05-31 · Disposition to issuer · Disposed 294,799 · Balance 0 F3: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock ("Company Option") that was outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested, with a per share exercise price that was less than the Merger Consideration, was cancelled and converted into the right to receive a cash amount, without interest and less any applicable withholding taxes, equal to the product of (i) the aggregate number of shares of Common Stock underlying such Company Option immediately prior to the Effective Time, and (ii) the excess of (A) the Merger Consideration over (B) the per share exercise price of such Company Option. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $17.00 · Expires 2029-03-06 | Direct | 0 |
Reported balance
After 2024-05-31 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2024-05-31 · Disposition to issuer · Disposed 81,967 · Balance 0 F3: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock ("Company Option") that was outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested, with a per share exercise price that was less than the Merger Consideration, was cancelled and converted into the right to receive a cash amount, without interest and less any applicable withholding taxes, equal to the product of (i) the aggregate number of shares of Common Stock underlying such Company Option immediately prior to the Effective Time, and (ii) the excess of (A) the Merger Consideration over (B) the per share exercise price of such Company Option. |
| Performance Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2024-05-31 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2024-05-31 · Disposition to issuer · Disposed 100,810 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each RSU subject to performance-based vesting conditions ("PSU") outstanding immediately prior to the Effective Time, whether vested or unvested, was canceled and converted into the right to receive a cash amount, without interest and less any applicable withholding taxes, equal to the product of (i) the aggregate number of shares of Common Stock underlying such PSU (assuming attainment of (A) the actual level of performance for performance metrics for which the relevant performance period had been completed as of the Effective Time and (B) the maximum level of performance under the terms of the applicable award agreement as in effect on the date of the Merger Agreement for performance metrics for which the relevant performance period had not been completed as of the Effective Time) and (ii) the Merger Consideration. F5: (Continued from Footnote 4) The amount reported represents PSUs for which performance was deemed achieved assuming attainment of maximum level of performance. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports the disposition of securities pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of April 4, 2024, by and among the Issuer, Johnson & Johnson ("J&J"), and Sweep Merger Sub, Inc., a wholly owned subsidiary of J&J ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer (the "Merger"), effective as of the effective time of the Merger (the "Effective Time"), with the Issuer surviving the Merger as a wholly owned subsidiary of J&J. As a result of the Merger, at the Effective Time, each outstanding share of common stock, par value $0.001 per share, of the Issuer ("Common Stock") outstanding immediately prior to the Effective Time (excluding Excluded Shares and any Dissenting Company Shares, each as defined in the Merger Agreement) was automatically converted into the right to receive $335.00 in cash (the "Merger Consideration"),
F2: (Continued from Footnote 1) without interest and less any applicable withholding taxes. Additionally, pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit ("RSU") outstanding immediately prior to the Effective Time, whether vested or unvested, was cancelled and converted into the right to receive a cash amount, without interest and less any applicable withholding taxes, equal to the product of (i) the aggregate number of shares of Common Stock underlying such RSU immediately prior to the Effective Time and (ii) the Merger Consideration.
F3: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock ("Company Option") that was outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested, with a per share exercise price that was less than the Merger Consideration, was cancelled and converted into the right to receive a cash amount, without interest and less any applicable withholding taxes, equal to the product of (i) the aggregate number of shares of Common Stock underlying such Company Option immediately prior to the Effective Time, and (ii) the excess of (A) the Merger Consideration over (B) the per share exercise price of such Company Option.
F4: Pursuant to the Merger Agreement, at the Effective Time, each RSU subject to performance-based vesting conditions ("PSU") outstanding immediately prior to the Effective Time, whether vested or unvested, was canceled and converted into the right to receive a cash amount, without interest and less any applicable withholding taxes, equal to the product of (i) the aggregate number of shares of Common Stock underlying such PSU (assuming attainment of (A) the actual level of performance for performance metrics for which the relevant performance period had been completed as of the Effective Time and (B) the maximum level of performance under the terms of the applicable award agreement as in effect on the date of the Merger Agreement for performance metrics for which the relevant performance period had not been completed as of the Effective Time) and (ii) the Merger Consideration.
F5: (Continued from Footnote 4) The amount reported represents PSUs for which performance was deemed achieved assuming attainment of maximum level of performance.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 31, 2024 Filed May 31, 2024 16:24 UTC | Shockwave Medical, Inc. SWAV · Entity 90374 | Disposition to issuerPerformance Stock Unit · Derivative | 100,810 | Not disclosed Strike: $0.00 | Not disclosed |
DisclosureSEC source: 0001642545-24-000110 · wk-form4_1717187088.xml · derivative · entry 4 Godshall Douglas Evan · CIK 0001404227 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 100,810 shares Expires not disclosed F4 · price: Pursuant to the Merger Agreement, at the Effective Time, each RSU subject to performance-based vesting conditions ("PSU") outstanding immediately prior to the Effective Time, whether vested or unvested, was canceled and converted into the right to receive a cash amount, without interest and less any applicable withholding taxes, equal to the product of (i) the aggregate number of shares of Common Stock underlying such PSU (assuming attainment of (A) the actual level of performance for performance metrics for which the relevant performance period had been completed as of the Effective Time and (B) the maximum level of performance under the terms of the applicable award agreement as in effect on the date of the Merger Agreement for performance metrics for which the relevant performance period had not been completed as of the Effective Time) and (ii) the Merger Consideration. F5 · price: (Continued from Footnote 4) The amount reported represents PSUs for which performance was deemed achieved assuming attainment of maximum level of performance. F4 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each RSU subject to performance-based vesting conditions ("PSU") outstanding immediately prior to the Effective Time, whether vested or unvested, was canceled and converted into the right to receive a cash amount, without interest and less any applicable withholding taxes, equal to the product of (i) the aggregate number of shares of Common Stock underlying such PSU (assuming attainment of (A) the actual level of performance for performance metrics for which the relevant performance period had been completed as of the Effective Time and (B) the maximum level of performance under the terms of the applicable award agreement as in effect on the date of the Merger Agreement for performance metrics for which the relevant performance period had not been completed as of the Effective Time) and (ii) the Merger Consideration. F5 · derivative.exercise_date: (Continued from Footnote 4) The amount reported represents PSUs for which performance was deemed achieved assuming attainment of maximum level of performance. F4 · derivative.expiration_date: Pursuant to the Merger Agreement, at the Effective Time, each RSU subject to performance-based vesting conditions ("PSU") outstanding immediately prior to the Effective Time, whether vested or unvested, was canceled and converted into the right to receive a cash amount, without interest and less any applicable withholding taxes, equal to the product of (i) the aggregate number of shares of Common Stock underlying such PSU (assuming attainment of (A) the actual level of performance for performance metrics for which the relevant performance period had been completed as of the Effective Time and (B) the maximum level of performance under the terms of the applicable award agreement as in effect on the date of the Merger Agreement for performance metrics for which the relevant performance period had not been completed as of the Effective Time) and (ii) the Merger Consideration. F5 · derivative.expiration_date: (Continued from Footnote 4) The amount reported represents PSUs for which performance was deemed achieved assuming attainment of maximum level of performance. Read SEC document |
| May 31, 2024 Filed May 31, 2024 16:24 UTC | Shockwave Medical, Inc. SWAV · Entity 90374 | Disposition to issuerStock Option · Derivative | 81,967 | Not disclosed Strike: $17.00 | Not disclosed |
DisclosureSEC source: 0001642545-24-000110 · wk-form4_1717187088.xml · derivative · entry 3 Godshall Douglas Evan · CIK 0001404227 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 81,967 shares Expires 2029-03-06 F3 · price: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock ("Company Option") that was outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested, with a per share exercise price that was less than the Merger Consideration, was cancelled and converted into the right to receive a cash amount, without interest and less any applicable withholding taxes, equal to the product of (i) the aggregate number of shares of Common Stock underlying such Company Option immediately prior to the Effective Time, and (ii) the excess of (A) the Merger Consideration over (B) the per share exercise price of such Company Option. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock ("Company Option") that was outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested, with a per share exercise price that was less than the Merger Consideration, was cancelled and converted into the right to receive a cash amount, without interest and less any applicable withholding taxes, equal to the product of (i) the aggregate number of shares of Common Stock underlying such Company Option immediately prior to the Effective Time, and (ii) the excess of (A) the Merger Consideration over (B) the per share exercise price of such Company Option. Read SEC document |
| May 31, 2024 Filed May 31, 2024 16:24 UTC | Shockwave Medical, Inc. SWAV · Entity 90374 | Disposition to issuerStock Option · Derivative | 294,799 | Not disclosed Strike: $3.42 | Not disclosed |
DisclosureSEC source: 0001642545-24-000110 · wk-form4_1717187088.xml · derivative · entry 2 Godshall Douglas Evan · CIK 0001404227 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 294,799 shares Expires 2027-05-09 F3 · price: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock ("Company Option") that was outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested, with a per share exercise price that was less than the Merger Consideration, was cancelled and converted into the right to receive a cash amount, without interest and less any applicable withholding taxes, equal to the product of (i) the aggregate number of shares of Common Stock underlying such Company Option immediately prior to the Effective Time, and (ii) the excess of (A) the Merger Consideration over (B) the per share exercise price of such Company Option. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock ("Company Option") that was outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested, with a per share exercise price that was less than the Merger Consideration, was cancelled and converted into the right to receive a cash amount, without interest and less any applicable withholding taxes, equal to the product of (i) the aggregate number of shares of Common Stock underlying such Company Option immediately prior to the Effective Time, and (ii) the excess of (A) the Merger Consideration over (B) the per share exercise price of such Company Option. Read SEC document |
| May 31, 2024 Filed May 31, 2024 16:24 UTC | Shockwave Medical, Inc. SWAV · Entity 90374 | Disposition to issuerCommon Stock | 151,629 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001642545-24-000110 · wk-form4_1717187088.xml · nonDerivative · entry 1 Godshall Douglas Evan · CIK 0001404227 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · price: This Form 4 reports the disposition of securities pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of April 4, 2024, by and among the Issuer, Johnson & Johnson ("J&J"), and Sweep Merger Sub, Inc., a wholly owned subsidiary of J&J ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer (the "Merger"), effective as of the effective time of the Merger (the "Effective Time"), with the Issuer surviving the Merger as a wholly owned subsidiary of J&J. As a result of the Merger, at the Effective Time, each outstanding share of common stock, par value $0.001 per share, of the Issuer ("Common Stock") outstanding immediately prior to the Effective Time (excluding Excluded Shares and any Dissenting Company Shares, each as defined in the Merger Agreement) was automatically converted into the right to receive $335.00 in cash (the "Merger Consideration"), F2 · price: (Continued from Footnote 1) without interest and less any applicable withholding taxes. Additionally, pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit ("RSU") outstanding immediately prior to the Effective Time, whether vested or unvested, was cancelled and converted into the right to receive a cash amount, without interest and less any applicable withholding taxes, equal to the product of (i) the aggregate number of shares of Common Stock underlying such RSU immediately prior to the Effective Time and (ii) the Merger Consideration. Read SEC document |
| May 02, 2024 Filed May 3, 2024 19:53 UTC | Shockwave Medical, Inc. SWAV · Entity 90374 | Tax withholdingCommon Stock | 552 | $329.81 | $182,055.12 |
DisclosureSEC source: 0001642545-24-000086 · wk-form4_1714780424.xml · nonDerivative · entry 2 Godshall Douglas Evan · CIK 0001404227 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 151,629 Read SEC document |
| May 02, 2024 Filed May 3, 2024 19:53 UTC | Shockwave Medical, Inc. SWAV · Entity 90374 | Tax withholdingCommon Stock | 592 | $329.81 | $195,247.52 |
DisclosureSEC source: 0001642545-24-000086 · wk-form4_1714780424.xml · nonDerivative · entry 1 Godshall Douglas Evan · CIK 0001404227 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 152,181 Read SEC document |
| February 20, 2024 Filed Feb 21, 2024 20:52 UTC | Shockwave Medical, Inc. SWAV · Entity 90374 | Tax withholdingCommon Stock | 9,989 | $255.67 | $2,553,887.63 |
DisclosureSEC source: 0001642545-24-000048 · wk-form4_1708566763.xml · nonDerivative · entry 1 Godshall Douglas Evan · CIK 0001404227 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 152,773 Read SEC document |
| February 15, 2024 Filed Feb 16, 2024 20:02 UTC | Shockwave Medical, Inc. SWAV · Entity 90374 | Exercise / conversionStock Option · Derivative | 10,000 | $0.00 Strike: $3.42 | $0.00 |
DisclosureSEC source: 0001642545-24-000044 · wk-form4_1708131730.xml · derivative · entry 10 Godshall Douglas Evan · CIK 0001404227 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 294,799 Underlying: Common Stock · 10,000 shares Expires 2027-05-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All transactions reported here were effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person on 05/25/2023. F10 · derivative.exercise_date: Fully vested. Read SEC document |
| February 15, 2024 Filed Feb 16, 2024 20:02 UTC | Shockwave Medical, Inc. SWAV · Entity 90374 | SaleCommon Stock | 831 | $236.13 | $196,224.03 |
DisclosureSEC source: 0001642545-24-000044 · wk-form4_1708131730.xml · nonDerivative · entry 9 Godshall Douglas Evan · CIK 0001404227 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 162,762 F1 · kind: All transactions reported here were effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person on 05/25/2023. F9 · price: The price reported in Column 4 is a weighted average price. The reported securities were sold in multiple transactions at prices ranging from $235.99 to $236.51. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. Read SEC document |
| February 15, 2024 Filed Feb 16, 2024 20:02 UTC | Shockwave Medical, Inc. SWAV · Entity 90374 | SaleCommon Stock | 600 | $235.21 | $141,126.00 |
DisclosureSEC source: 0001642545-24-000044 · wk-form4_1708131730.xml · nonDerivative · entry 8 Godshall Douglas Evan · CIK 0001404227 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 163,593 F1 · kind: All transactions reported here were effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person on 05/25/2023. F8 · price: The price reported in Column 4 is a weighted average price. The reported securities were sold in multiple transactions at prices ranging from $234.91 to $235.53. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. Read SEC document |
| February 15, 2024 Filed Feb 16, 2024 20:02 UTC | Shockwave Medical, Inc. SWAV · Entity 90374 | SaleCommon Stock | 200 | $233.54 | $46,708.00 |
DisclosureSEC source: 0001642545-24-000044 · wk-form4_1708131730.xml · nonDerivative · entry 7 Godshall Douglas Evan · CIK 0001404227 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 164,193 F1 · kind: All transactions reported here were effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person on 05/25/2023. F7 · price: All reported securities were sold at a price of $233.54. Read SEC document |
| February 15, 2024 Filed Feb 16, 2024 20:02 UTC | Shockwave Medical, Inc. SWAV · Entity 90374 | SaleCommon Stock | 792 | $232.74 | $184,330.08 |
DisclosureSEC source: 0001642545-24-000044 · wk-form4_1708131730.xml · nonDerivative · entry 6 Godshall Douglas Evan · CIK 0001404227 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 164,393 F1 · kind: All transactions reported here were effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person on 05/25/2023. F6 · price: The price reported in Column 4 is a weighted average price. The reported securities were sold in multiple transactions at prices ranging from $232.37 to $233.25. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. Read SEC document |
| February 15, 2024 Filed Feb 16, 2024 20:02 UTC | Shockwave Medical, Inc. SWAV · Entity 90374 | SaleCommon Stock | 1,987 | $231.74 | $460,467.38 |
DisclosureSEC source: 0001642545-24-000044 · wk-form4_1708131730.xml · nonDerivative · entry 5 Godshall Douglas Evan · CIK 0001404227 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 165,185 F1 · kind: All transactions reported here were effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person on 05/25/2023. F5 · price: The price reported in Column 4 is a weighted average price. The reported securities were sold in multiple transactions at prices ranging from $231.35 to $232.18. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. Read SEC document |
| February 15, 2024 Filed Feb 16, 2024 20:02 UTC | Shockwave Medical, Inc. SWAV · Entity 90374 | SaleCommon Stock | 2,800 | $230.86 | $646,408.00 |
DisclosureSEC source: 0001642545-24-000044 · wk-form4_1708131730.xml · nonDerivative · entry 4 Godshall Douglas Evan · CIK 0001404227 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 167,172 F1 · kind: All transactions reported here were effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person on 05/25/2023. F4 · price: The price reported in Column 4 is a weighted average price. The reported securities were sold in multiple transactions at prices ranging from $230.32 to $231.24. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. Read SEC document |
| February 15, 2024 Filed Feb 16, 2024 20:02 UTC | Shockwave Medical, Inc. SWAV · Entity 90374 | SaleCommon Stock | 2,230 | $229.82 | $512,498.60 |
DisclosureSEC source: 0001642545-24-000044 · wk-form4_1708131730.xml · nonDerivative · entry 3 Godshall Douglas Evan · CIK 0001404227 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 169,972 F1 · kind: All transactions reported here were effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person on 05/25/2023. F3 · price: The price reported in Column 4 is a weighted average price. The reported securities were sold in multiple transactions at prices ranging from $229.12 to $230.08. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. Read SEC document |
| February 15, 2024 Filed Feb 16, 2024 20:02 UTC | Shockwave Medical, Inc. SWAV · Entity 90374 | SaleCommon Stock | 560 | $228.28 | $127,836.80 |
DisclosureSEC source: 0001642545-24-000044 · wk-form4_1708131730.xml · nonDerivative · entry 2 Godshall Douglas Evan · CIK 0001404227 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 172,202 F1 · kind: All transactions reported here were effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person on 05/25/2023. F2 · price: The price reported in Column 4 is a weighted average price. The reported securities were sold in multiple transactions at prices ranging from $227.95 to $228.82. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. Read SEC document |
| February 15, 2024 Filed Feb 16, 2024 20:02 UTC | Shockwave Medical, Inc. SWAV · Entity 90374 | Exercise / conversionCommon Stock | 10,000 | $3.42 | $34,160.00 |
DisclosureSEC source: 0001642545-24-000044 · wk-form4_1708131730.xml · nonDerivative · entry 1 Godshall Douglas Evan · CIK 0001404227 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 172,762 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All transactions reported here were effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person on 05/25/2023. Read SEC document |
| February 05, 2024 Filed Feb 6, 2024 20:12 UTC | Shockwave Medical, Inc. SWAV · Entity 90374 | Tax withholdingCommon Stock | 604 | $226.30 | $136,685.20 |
DisclosureSEC source: 0001642545-24-000036 · wk-form4_1707268368.xml · nonDerivative · entry 3 Godshall Douglas Evan · CIK 0001404227 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 162,762 Read SEC document |
| February 05, 2024 Filed Feb 6, 2024 20:12 UTC | Shockwave Medical, Inc. SWAV · Entity 90374 | Tax withholdingCommon Stock | 2,614 | $226.28 | $591,495.92 |
DisclosureSEC source: 0001642545-24-000036 · wk-form4_1707268368.xml · nonDerivative · entry 2 Godshall Douglas Evan · CIK 0001404227 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 163,366 Read SEC document |
| February 05, 2024 Filed Feb 6, 2024 20:12 UTC | Shockwave Medical, Inc. SWAV · Entity 90374 | Tax withholdingCommon Stock | 5,918 | $226.30 | $1,339,243.40 |
DisclosureSEC source: 0001642545-24-000036 · wk-form4_1707268368.xml · nonDerivative · entry 1 Godshall Douglas Evan · CIK 0001404227 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 165,980 Read SEC document |
| February 01, 2024 Filed Feb 2, 2024 20:06 UTC | Shockwave Medical, Inc. SWAV · Entity 90374 | GrantCommon Stock | 19,013 | $0.00 | $0.00 |
DisclosureSEC source: 0001642545-24-000024 · wk-form4_1706922390.xml · nonDerivative · entry 1 Godshall Douglas Evan · CIK 0001404227 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 171,898 Read SEC document |
| January 18, 2024 Filed Jan 18, 2024 20:15 UTC | Shockwave Medical, Inc. SWAV · Entity 90374 | Tax withholdingCommon Stock | 10,250 | $217.78 | $2,232,245.00 |
DisclosureSEC source: 0001642545-24-000012 · wk-form4_1705626913.xml · nonDerivative · entry 8 Godshall Douglas Evan · CIK 0001404227 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 152,885 Read SEC document |
| January 17, 2024 Filed Jan 18, 2024 20:15 UTC | Shockwave Medical, Inc. SWAV · Entity 90374 | GrantCommon Stock | 22,078 | $0.00 | $0.00 |
DisclosureSEC source: 0001642545-24-000012 · wk-form4_1705626913.xml · nonDerivative · entry 7 Godshall Douglas Evan · CIK 0001404227 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 163,135 F7 · shares: Represents the vesting and settlement of a performance-based restricted stock unit award granted on February 1, 2022, resulting from the achievement of certain performance criteria related to the compound annual growth rate of the Issuers revenue during the measurement period January 1, 2022 through December 31, 2023. Read SEC document |
| January 16, 2024 Filed Jan 18, 2024 20:15 UTC | Shockwave Medical, Inc. SWAV · Entity 90374 | Exercise / conversionStock Option · Derivative | 10,000 | $0.00 Strike: $3.42 | $0.00 |
DisclosureSEC source: 0001642545-24-000012 · wk-form4_1705626913.xml · derivative · entry 9 Godshall Douglas Evan · CIK 0001404227 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 304,799 Underlying: Common Stock · 10,000 shares Expires 2027-05-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All transactions reported here were effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person on 5/25/2023. F8 · derivative.exercise_date: Fully vested. Read SEC document |
| January 16, 2024 Filed Jan 18, 2024 20:15 UTC | Shockwave Medical, Inc. SWAV · Entity 90374 | SaleCommon Stock | 1,000 | $220.00 | $220,000.00 |
DisclosureSEC source: 0001642545-24-000012 · wk-form4_1705626913.xml · nonDerivative · entry 6 Godshall Douglas Evan · CIK 0001404227 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 141,057 F1 · kind: All transactions reported here were effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person on 5/25/2023. F6 · price: The price reported in Column 4 is a weighted average price. The reported securities were sold in multiple transactions at prices ranging from $219.79 to $220.29. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. Read SEC document |
| January 16, 2024 Filed Jan 18, 2024 20:15 UTC | Shockwave Medical, Inc. SWAV · Entity 90374 | SaleCommon Stock | 1,248 | $219.27 | $273,648.96 |
DisclosureSEC source: 0001642545-24-000012 · wk-form4_1705626913.xml · nonDerivative · entry 5 Godshall Douglas Evan · CIK 0001404227 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 142,057 F1 · kind: All transactions reported here were effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person on 5/25/2023. F5 · price: The price reported in Column 4 is a weighted average price. The reported securities were sold in multiple transactions at prices ranging from $218.70 to $219.58. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. Read SEC document |
| January 16, 2024 Filed Jan 18, 2024 20:15 UTC | Shockwave Medical, Inc. SWAV · Entity 90374 | SaleCommon Stock | 1,302 | $217.97 | $283,796.94 |
DisclosureSEC source: 0001642545-24-000012 · wk-form4_1705626913.xml · nonDerivative · entry 4 Godshall Douglas Evan · CIK 0001404227 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 143,305 F1 · kind: All transactions reported here were effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person on 5/25/2023. F4 · price: The price reported in Column 4 is a weighted average price. The reported securities were sold in multiple transactions at prices ranging from $217.49 to $218.43. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. Read SEC document |
| January 16, 2024 Filed Jan 18, 2024 20:15 UTC | Shockwave Medical, Inc. SWAV · Entity 90374 | SaleCommon Stock | 6,150 | $216.87 | $1,333,750.50 |
DisclosureSEC source: 0001642545-24-000012 · wk-form4_1705626913.xml · nonDerivative · entry 3 Godshall Douglas Evan · CIK 0001404227 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 144,607 F1 · kind: All transactions reported here were effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person on 5/25/2023. F3 · price: The price reported in Column 4 is a weighted average price. The reported securities were sold in multiple transactions at prices ranging from $216.47 to $217.41. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. Read SEC document |
| January 16, 2024 Filed Jan 18, 2024 20:15 UTC | Shockwave Medical, Inc. SWAV · Entity 90374 | SaleCommon Stock | 300 | $215.54 | $64,662.00 |
DisclosureSEC source: 0001642545-24-000012 · wk-form4_1705626913.xml · nonDerivative · entry 2 Godshall Douglas Evan · CIK 0001404227 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 150,757 F1 · kind: All transactions reported here were effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person on 5/25/2023. F2 · price: The price reported in Column 4 is a weighted average price. The reported securities were sold in multiple transactions at prices ranging from $215.23 to $216.18. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. Read SEC document |
| January 16, 2024 Filed Jan 18, 2024 20:15 UTC | Shockwave Medical, Inc. SWAV · Entity 90374 | Exercise / conversionCommon Stock | 10,000 | $3.42 | $34,160.00 |
DisclosureSEC source: 0001642545-24-000012 · wk-form4_1705626913.xml · nonDerivative · entry 1 Godshall Douglas Evan · CIK 0001404227 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 151,057 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All transactions reported here were effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person on 5/25/2023. Read SEC document |
| January 05, 2024 Filed Jan 8, 2024 20:18 UTC | Shockwave Medical, Inc. SWAV · Entity 90374 | Exercise / conversionStock Option · Derivative | 10,000 | $0.00 Strike: $3.42 | $0.00 |
DisclosureSEC source: 0001642545-24-000004 · wk-form4_1704763128.xml · derivative · entry 3 Godshall Douglas Evan · CIK 0001404227 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 314,799 Underlying: Common Stock · 10,000 shares Expires 2027-05-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All transactions reported here were effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person on 5/25/2023. F3 · derivative.exercise_date: Fully vested. Read SEC document |
| January 05, 2024 Filed Jan 8, 2024 20:18 UTC | Shockwave Medical, Inc. SWAV · Entity 90374 | SaleCommon Stock | 10,000 | $200.05 | $2,000,500.00 |
DisclosureSEC source: 0001642545-24-000004 · wk-form4_1704763128.xml · nonDerivative · entry 2 Godshall Douglas Evan · CIK 0001404227 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 141,057 F1 · kind: All transactions reported here were effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person on 5/25/2023. F2 · price: The price reported in Column 4 is a weighted average price. The reported securities were sold in multiple transactions at prices ranging from $200.00 to $200.29. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. Read SEC document |
| January 05, 2024 Filed Jan 8, 2024 20:18 UTC | Shockwave Medical, Inc. SWAV · Entity 90374 | Exercise / conversionCommon Stock | 10,000 | $3.42 | $34,160.00 |
DisclosureSEC source: 0001642545-24-000004 · wk-form4_1704763128.xml · nonDerivative · entry 1 Godshall Douglas Evan · CIK 0001404227 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 151,057 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All transactions reported here were effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person on 5/25/2023. Read SEC document |
| December 15, 2023 Filed Dec 18, 2023 20:09 UTC | Shockwave Medical, Inc. SWAV · Entity 90374 | Exercise / conversionStock Option · Derivative | 5,000 | $0.00 Strike: $3.42 | $0.00 |
DisclosureSEC source: 0001642545-23-000053 · wk-form4_1702948159.xml · derivative · entry 7 Godshall Douglas Evan · CIK 0001404227 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 324,799 Underlying: Common Stock · 5,000 shares Expires 2027-05-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All transactions reported here were effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person on 5/25/2023. F7 · derivative.exercise_date: Fully vested. Read SEC document |
| December 15, 2023 Filed Dec 18, 2023 20:09 UTC | Shockwave Medical, Inc. SWAV · Entity 90374 | SaleCommon Stock | 200 | $191.03 | $38,206.00 |
DisclosureSEC source: 0001642545-23-000053 · wk-form4_1702948159.xml · nonDerivative · entry 6 Godshall Douglas Evan · CIK 0001404227 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 141,057 F1 · kind: All transactions reported here were effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person on 5/25/2023. F6 · price: The price reported in Column 4 is a weighted average price. The reported securities were sold in multiple transactions at prices ranging from $191.00 to $191.05. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. Read SEC document |
| December 15, 2023 Filed Dec 18, 2023 20:09 UTC | Shockwave Medical, Inc. SWAV · Entity 90374 | SaleCommon Stock | 359 | $190.03 | $68,220.77 |
DisclosureSEC source: 0001642545-23-000053 · wk-form4_1702948159.xml · nonDerivative · entry 5 Godshall Douglas Evan · CIK 0001404227 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 141,257 F1 · kind: All transactions reported here were effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person on 5/25/2023. F5 · price: The price reported in Column 4 is a weighted average price. The reported securities were sold in multiple transactions at prices ranging from $189.98 to $190.18. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. Read SEC document |
| December 15, 2023 Filed Dec 18, 2023 20:09 UTC | Shockwave Medical, Inc. SWAV · Entity 90374 | SaleCommon Stock | 700 | $188.47 | $131,929.00 |
DisclosureSEC source: 0001642545-23-000053 · wk-form4_1702948159.xml · nonDerivative · entry 4 Godshall Douglas Evan · CIK 0001404227 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 141,616 F1 · kind: All transactions reported here were effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person on 5/25/2023. F4 · price: The price reported in Column 4 is a weighted average price. The reported securities were sold in multiple transactions at prices ranging from $188.25 to $189.01. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. Read SEC document |
| December 15, 2023 Filed Dec 18, 2023 20:09 UTC | Shockwave Medical, Inc. SWAV · Entity 90374 | SaleCommon Stock | 2,293 | $187.56 | $430,075.08 |
DisclosureSEC source: 0001642545-23-000053 · wk-form4_1702948159.xml · nonDerivative · entry 3 Godshall Douglas Evan · CIK 0001404227 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 142,316 F1 · kind: All transactions reported here were effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person on 5/25/2023. F3 · price: The price reported in Column 4 is a weighted average price. The reported securities were sold in multiple transactions at prices ranging from $187.24 to $188.08. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. Read SEC document |
| December 15, 2023 Filed Dec 18, 2023 20:09 UTC | Shockwave Medical, Inc. SWAV · Entity 90374 | SaleCommon Stock | 1,448 | $186.84 | $270,544.32 |
DisclosureSEC source: 0001642545-23-000053 · wk-form4_1702948159.xml · nonDerivative · entry 2 Godshall Douglas Evan · CIK 0001404227 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 144,609 F1 · kind: All transactions reported here were effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person on 5/25/2023. F2 · price: The price reported in Column 4 is a weighted average price. The reported securities were sold in multiple transactions at prices ranging from $186.24 to $187.22. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. Read SEC document |
| December 15, 2023 Filed Dec 18, 2023 20:09 UTC | Shockwave Medical, Inc. SWAV · Entity 90374 | Exercise / conversionCommon Stock | 5,000 | $3.42 | $17,080.00 |
DisclosureSEC source: 0001642545-23-000053 · wk-form4_1702948159.xml · nonDerivative · entry 1 Godshall Douglas Evan · CIK 0001404227 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 146,057 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All transactions reported here were effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person on 5/25/2023. Read SEC document |
| November 15, 2023 Filed Nov 17, 2023 20:00 UTC | Shockwave Medical, Inc. SWAV · Entity 90374 | Exercise / conversionStock Option · Derivative | 5,000 | $0.00 Strike: $3.42 | $0.00 |
DisclosureSEC source: 0001209191-23-055916 · doc4.xml · derivative · entry 8 Godshall Douglas Evan · CIK 0001404227 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 329,799 Underlying: Common Stock · 5,000 shares Expires 2027-05-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All transactions reported here were effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person on 5/25/2023. F8 · derivative.exercise_date: Twenty-Five percent of the shares subject to this option vested on 5/9/18 and the balance of the shares vested in equal monthly installments. Read SEC document |
| November 15, 2023 Filed Nov 17, 2023 20:00 UTC | Shockwave Medical, Inc. SWAV · Entity 90374 | Exercise / conversionCommon Stock | 5,000 | $3.42 | $17,080.00 |
DisclosureSEC source: 0001209191-23-055916 · doc4.xml · nonDerivative · entry 7 Godshall Douglas Evan · CIK 0001404227 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 141,057 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All transactions reported here were effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person on 5/25/2023. Read SEC document |
| November 15, 2023 Filed Nov 17, 2023 20:00 UTC | Shockwave Medical, Inc. SWAV · Entity 90374 | SaleCommon Stock | 400 | $177.02 | $70,808.00 |
DisclosureSEC source: 0001209191-23-055916 · doc4.xml · nonDerivative · entry 6 Godshall Douglas Evan · CIK 0001404227 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 136,057 F1 · kind: All transactions reported here were effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person on 5/25/2023. F7 · price: The price reported in Column 4 is a weighted average price. The reported securities were sold in multiple transactions at prices ranging from $176.65 to $177.52. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. Read SEC document |
| November 15, 2023 Filed Nov 17, 2023 20:00 UTC | Shockwave Medical, Inc. SWAV · Entity 90374 | SaleCommon Stock | 914 | $175.82 | $160,699.48 |
DisclosureSEC source: 0001209191-23-055916 · doc4.xml · nonDerivative · entry 5 Godshall Douglas Evan · CIK 0001404227 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 136,457 F1 · kind: All transactions reported here were effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person on 5/25/2023. F6 · price: The price reported in Column 4 is a weighted average price. The reported securities were sold in multiple transactions at prices ranging from $175.48 to $176.31. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. Read SEC document |
| November 15, 2023 Filed Nov 17, 2023 20:00 UTC | Shockwave Medical, Inc. SWAV · Entity 90374 | SaleCommon Stock | 1,186 | $175.11 | $207,680.46 |
DisclosureSEC source: 0001209191-23-055916 · doc4.xml · nonDerivative · entry 4 Godshall Douglas Evan · CIK 0001404227 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 137,371 F1 · kind: All transactions reported here were effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person on 5/25/2023. F5 · price: The price reported in Column 4 is a weighted average price. The reported securities were sold in multiple transactions at prices ranging from $174.48 to $175.43. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. Read SEC document |
| November 15, 2023 Filed Nov 17, 2023 20:00 UTC | Shockwave Medical, Inc. SWAV · Entity 90374 | SaleCommon Stock | 500 | $173.93 | $86,965.00 |
DisclosureSEC source: 0001209191-23-055916 · doc4.xml · nonDerivative · entry 3 Godshall Douglas Evan · CIK 0001404227 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 138,557 F1 · kind: All transactions reported here were effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person on 5/25/2023. F4 · price: The price reported in Column 4 is a weighted average price. The reported securities were sold in multiple transactions at prices ranging from $173.44 to $174.38. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. Read SEC document |
| November 15, 2023 Filed Nov 17, 2023 20:00 UTC | Shockwave Medical, Inc. SWAV · Entity 90374 | SaleCommon Stock | 900 | $172.82 | $155,538.00 |
DisclosureSEC source: 0001209191-23-055916 · doc4.xml · nonDerivative · entry 2 Godshall Douglas Evan · CIK 0001404227 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 139,057 F1 · kind: All transactions reported here were effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person on 5/25/2023. F3 · price: The price reported in Column 4 is a weighted average price. The reported securities were sold in multiple transactions at prices ranging from $172.30 to $173.09. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. Read SEC document |
| November 15, 2023 Filed Nov 17, 2023 20:00 UTC | Shockwave Medical, Inc. SWAV · Entity 90374 | SaleCommon Stock | 1,100 | $171.56 | $188,716.00 |
DisclosureSEC source: 0001209191-23-055916 · doc4.xml · nonDerivative · entry 1 Godshall Douglas Evan · CIK 0001404227 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 139,957 F1 · kind: All transactions reported here were effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person on 5/25/2023. F2 · price: The price reported in Column 4 is a weighted average price. The reported securities were sold in multiple transactions at prices ranging from $171.16 to $172.15. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. Read SEC document |
| November 02, 2023 Filed Nov 15, 2023 20:14 UTC | Shockwave Medical, Inc. SWAV · Entity 90374 | Tax withholdingCommon Stock | 592 | $214.07 | $126,729.44 |
DisclosureSEC source: 0001209191-23-055435 · doc4.xml · nonDerivative · entry 1 Godshall Douglas Evan · CIK 0001404227 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 141,057 F1 · price: All reported securities were sold at a price of $214.07. Read SEC document |
| October 16, 2023 Filed Oct 17, 2023 20:10 UTC | Shockwave Medical, Inc. SWAV · Entity 90374 | Exercise / conversionStock Option · Derivative | 10,000 | $0.00 Strike: $3.42 | $0.00 |
DisclosureSEC source: 0001209191-23-053035 · doc4.xml · derivative · entry 9 Godshall Douglas Evan · CIK 0001404227 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 334,799 Underlying: Common Stock · 10,000 shares Expires 2027-05-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All transactions reported here were effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person on 5/25/2023. F9 · derivative.exercise_date: Twenty-Five percent of the shares subject to this option vested on 5/9/18 and the balance of the shares vested in equal monthly installments. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.